100763
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
阿利吉仑 (Aliskiren) 对高血压前期患者的心血管的影响：随机对照试验的综合分析
Authors Zhang JT, Chen KP, Guan T, Zhang S
Published Date April 2015 Volume 2015:9 Pages 1963—1971
DOI http://dx.doi.org/10.2147/DDDT.S75111
Received 29 September 2014, Accepted 29 October 2014, Published 2 April 2015
Background: Aliskiren is a widely used therapy for patients with hypertension,
however, the effect of aliskiren on major cardiovascular outcomes is a matter
of debate. The aim of this study is to evaluate the effects of aliskiren
therapy on major cardiovascular outcomes by this meta-analysis of randomized
controlled trials.
Methods: We searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials for relevant literature. All eligible studies were randomized controlled trials assessing the effect of aliskiren therapy compared with patients without aliskiren therapy. Relative risks (RRs) with 95% confidence intervals (CIs) were used to measure the effect of aliskiren therapy on major cardiovascular outcomes with a random-effect model.
Results: We included six trials reporting data on 12,465 patients. These studies reported 1,886 occurrences of major cardiovascular events, 1,074 events of total mortality, 739 events of cardiac death, 366 events of myocardial infarction, and 319 events of stroke. Aliskiren therapy had no effect on major cardiovascular events (RR, 0.93; 95% CI: 0.77–1.13; P =0.47), total mortality (RR, 1.00; 95% CI: 0.77–1.29; P =1.00), cardiac death (RR, 1.01; 95% CI: 0.79–1.29; P =0.95), myocardial infarction (RR, 0.71; 95% CI: 0.36–1.38; P =0.31), or stroke (RR, 0.87; 95% CI: 0.48–1.58; P =0.64).
Conclusion: Aliskiren therapy does not have an effect on the incidence of major cardiovascular events, total mortality, cardiac death, myocardial infarction, or stroke.
Keywords: aliskiren, cardiovascular disease, stroke, systematic review, meta-analysis
Methods: We searched PubMed, EmBase, and the Cochrane Central Register of Controlled Trials for relevant literature. All eligible studies were randomized controlled trials assessing the effect of aliskiren therapy compared with patients without aliskiren therapy. Relative risks (RRs) with 95% confidence intervals (CIs) were used to measure the effect of aliskiren therapy on major cardiovascular outcomes with a random-effect model.
Results: We included six trials reporting data on 12,465 patients. These studies reported 1,886 occurrences of major cardiovascular events, 1,074 events of total mortality, 739 events of cardiac death, 366 events of myocardial infarction, and 319 events of stroke. Aliskiren therapy had no effect on major cardiovascular events (RR, 0.93; 95% CI: 0.77–1.13; P =0.47), total mortality (RR, 1.00; 95% CI: 0.77–1.29; P =1.00), cardiac death (RR, 1.01; 95% CI: 0.79–1.29; P =0.95), myocardial infarction (RR, 0.71; 95% CI: 0.36–1.38; P =0.31), or stroke (RR, 0.87; 95% CI: 0.48–1.58; P =0.64).
Conclusion: Aliskiren therapy does not have an effect on the incidence of major cardiovascular events, total mortality, cardiac death, myocardial infarction, or stroke.
Keywords: aliskiren, cardiovascular disease, stroke, systematic review, meta-analysis
Download Article[PDF]
